Notes:
• Dulaglutide is a mildly effective hypoglycemic. It has shown benefit in type 2 diabetes patients with existing cardiovascular disease.

Initiation (new start) criteria: Non-formulary dulaglutide (Trulicity) will be covered on the prescription drug benefit when the following criteria are met:

• Diagnosis of type 2 diabetes, and
• Diagnosis of Atherosclerotic Cardiovascular Disease (ASCVD) [conditions include: acute coronary syndromes (ACS), history of myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, ischemic stroke, transient ischemic attack (TIA), or symptomatic peripheral arterial disease (PAD)], and
• Intolerance* to preferred GLP-1 inhibitor liraglutide (Victoza) and semaglutide (Ozempic) which are also CBC, and
• Patient has a recent HbA1c under 9, and
• No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and
• On maximally tolerated metformin dose (1500-2500mg) for at least 3 months (or allergy or intolerance* to metformin), and
• Taking an SGLT2-I (empagliflozin or canagliflozin) or failure/contraindication to taking an SGLT2-I*, and
• On maximally tolerated dose or patient has an allergy or intolerance* to statin, and
• On maximally tolerated dose or patient has an allergy or intolerance* to ACE/ARB, and

* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation